Betaxolol Market – Global Industry Insights, Trends, Opportunity Analysis, 2021-2027 the new research from Coherent Market Insights has announced report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The Betaxolol Market offers a summary of product specification, production analysis, technology, product type, considering key features such as gross margin, revenue & cost. Betaxolol Market report provides key statistics on the Market status of the Betaxolol manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1781
Betaxolol is the beta-adrenergic receptor inhibitor and racemic mixture used for treatment of patients having ocular hypertension or chronic open-angle glaucoma. It was initially approved, in 1989, by the U.S. Food and Drug Administration (FDA) for an oral tablet. The Betaxolol is either used alone or combined with other drugs for lowering down pressure in eye or the heart. Topical applications within the eye decreases secretion of aqueous humor along with lowering down the Intraocular Pressure (IOP) causing reduces risk of damage of optic nerve and vision loss in patients. However, drowsiness, dizziness, headache, and lightheadedness, are among the symptoms observed while taking the medication in initial stages. For administration orally, Betaxolol is accessible as 20-mg and 10-mg tablets, while in liquid form, it’s available in 15, 10, 5, 2.5 mL bottles with 0.25% sterile ophthalmic suspension, suggested as 1-2 drops within affected eye 2 times daily.
Global Betaxolol Market Drivers
Rising incidence of glaucoma globally is expected to propel the global betaxolol market growth over the forecast period. As per the Glaucoma research Foundation data, glaucoma is a major cause for irreversible blindness globally. Around 10% glaucoma patients, receiving proper treatments still suffer vision loss. Around 64.3 Mn populace was estimated to suffer from glaucoma globally, in 2013. Moreover, as per the American Academy of Ophthalmology, prevalence rate of glaucoma in Latin America and Africa is high. Patients failing to respond for medications, go through trabeculectomy surgeries. However, limited patients fail to achieve full cure from the glaucoma even post trabeculectomy surgery. Hence, novel options for treatment are needed to provide relief to these patients. Decreasing intra-ocular pressures are the most crucial long-term medical requirement for patients of refractory glaucoma, which could be overcome through the Betaxolol drug use, which is expected to drive the global betaxolol market growth over the forecast period. Moreover, populace affected by diabetic retinopathy is more likely to suffer from glaucoma. This condition is related with abnormal growth of blood vessel, which leads to retinopathy, resulting in blockage of the natural eye drainage. Thus, surge in patient pool of diabetes is expected to drive the global betaxolol market growth over the forecast period.
Increasing incidence of hypertension disorders is expected to fuel global betaxolol market over the forecast period. As per the reports by several sources, such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) in 2015, prevalence rate of pulmonary arterial hypertension globally is estimated to be over 100,000 to 200,000, meaning over 15 to 50 patients/million population. Though there is limited available treatment for pulmonary arterial hypertension, Prostacyclin and prostacyclin analogs, beta-adrenergic receptor inhibitor, and phosphodiesterase-5 (PDE-5) inhibitor are available for decreasing symptoms, slowing down progression of disease, and enhance the life’s quality.
Global Betaxolol Market Restraint
Strict regulatory approvals for ensuring the drug safety along with patent expiry of the betaxolol drugs including Betoptic Liq and Betoptic S, are key challenges expected to restrain growth of the global betaxolol market over the forecast period, since generic version of the drugs are being retailed at 70% – 80% low prices, than branded drugs.
Global Betaxolol Market – Regional Analysis
Based on geography, the global betaxolol market is segregated into North America, Europe, Latin America, Asia Pacific, Africa, and Middle East. North America accounts for the highest share in the global betaxolol market due to high incidence of eye-related disorders and diabetes among the population in this region. As per the National Federation of the blind, in 2014, over 1.3 million individuals in the U.S. were legally blind and around 75,000 people are expected to be affected by visual impairment or blindness annually. Furthermore, Asia Pacific is expected to register robust growth due to presence of generic companies including Lupin Ltd. And Cipla Ltd. specifically in India, that are focused on manufacturing of betaxolol generics for retaining the market position in this region.
Global Betaxolol Market – Competitive Landscape
Inorganic and organic strategies by manufacturers including merger, acquisition, R&D, and collaboration, to expand the business around the region is expected to drive the global betaxolol market growth over the forecast period. For instance, Humanwell Healthcare Group and PuraCap Pharmaceutical, in 2016, signed the acquisition of Epic Pharma LLC worth $550 million for expanding their manufacturing and commercial capabilities both, along with the presence within the U.S. as well as the global generics market.
Key players functioning in the global betaxolol market are Novartis AG, East West Pharma, Genix Pharma (Pvt.) Ltd., Hetero Healthcare Ltd. (GenX), Jawa Pharmaceuticals (INDIA) Pvt. Ltd., Cadila Pharmaceuticals Ltd., DAL Medical Services Company Ltd, Humanwell Healthcare Group, Sentiss Pharma Pvt. Ltd., PuraCap Pharmaceutical LLC., and others
Global Betaxolol Market Taxonomy
Based on Dosage Form
- Suspension
- Tablets
Based on Disease Indication
- Ocular Hypertension
- Glaucoma
Based on Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Buy This Complete Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/1781
Main points in Betaxolol Market Report Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Betaxolol Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Betaxolol Industry Impact
Chapter 2 Betaxolol Competition by Types, Applications, and Top Regions and Countries
2.1 Betaxolol (Volume and Value) by Type
2.3 Betaxolol (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Betaxolol Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Betaxolol Market Analysis
Chapter 6 East Asia Betaxolol Market Analysis
Chapter 7 Europe Betaxolol Market Analysis
Chapter 8 South Asia Betaxolol Market Analysis
Chapter 9 Southeast Asia Betaxolol Market Analysis
Chapter 10 Middle East Betaxolol Market Analysis
Chapter 11 Africa Betaxolol Market Analysis
Chapter 12 Oceania Betaxolol Market Analysis
Chapter 13 South America Betaxolol Market Analysis
Chapter 14 Company Profiles and Key Figures in Betaxolol Business
Chapter 15 Betaxolol Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
continued………….
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837